GIST is the most common mesenchymal tumour of the GI tract — and one of the great success stories of targeted cancer therapy. Imatinib (Gleevec) transformed GIST from a disease with limited treatment options to one where most localised GISTs are cured with surgery, and metastatic GISTs can be controlled for years with targeted oral therapy.
Gastrointestinal Stromal Tumours (GISTs) are the most common mesenchymal tumours of the GI tract — arising from the interstitial cells of Cajal (the pacemaker cells of the gut wall). They are defined by mutations in the KIT (CD117) proto-oncogene in 85% of cases, or the PDGFRA gene in 10%.
GISTs are fundamentally different from adenocarcinomas of the GI tract: they do not spread to lymph nodes, are highly sensitive to targeted tyrosine kinase inhibitors (imatinib), and surgical technique — specifically avoiding tumour rupture — is the single most important prognostic factor.
Molecular testing is mandatory for every GIST — before starting any systemic therapy. The specific mutation determines the optimal drug choice, dosing, and treatment strategy.
The primary site significantly influences biological behaviour, risk stratification, and surgical approach.
After surgical resection, every GIST is classified by risk of recurrence — based on tumour size, mitotic rate, and primary site.
| Risk Category | Tumour Size | Mitotic Rate | Recurrence Risk | Adjuvant Imatinib |
|---|---|---|---|---|
Very Low | <2 cm | <5/50 HPF | <2% | Not required |
Low | 2–5 cm | <5/50 HPF | 3–10% | Not required |
Intermediate | <5 cm | 5–10/50 HPF | 10–25% | Consider (discuss at MDT) |
High | >5 cm OR any size >10 mitoses | >10/50 HPF | 30–80%+ | 3 years adjuvant imatinib |
⚠️ Tumour Rupture = Automatic High Risk: Any GIST that has ruptured — regardless of size or mitotic rate — is classified as High Risk and requires 3 years of adjuvant imatinib. Rupture is the most important adverse prognostic factor in resected GIST.
The specific mutation determines the optimal drug, dose, and treatment strategy. Molecular testing must be performed on every GIST before starting any systemic therapy.
| Mutation | Imatinib Sensitivity | Clinical Notes |
|---|---|---|
KIT Exon 11 65–70% | Excellent response to imatinib 400mg daily | Most common GIST mutation. Best prognosis with imatinib. Median PFS on first-line imatinib 18–24 months for metastatic disease. |
KIT Exon 9 10–15% | Partial response — better with 800mg imatinib | Predominantly in small bowel GISTs. Higher imatinib dose (800 mg/day) significantly improves response. Sunitinib as second-line. |
PDGFRA D842V 5–8% | Resistant to imatinib AND sunitinib | The most important exception. Specifically treated with Avapritinib (Ayvakit). Response rate >90%. Mutation testing is critical. |
PDGFRA Other 3–5% | Variable imatinib sensitivity | Non-D842V PDGFRA mutations have variable imatinib response — treat and monitor carefully. |
Wild-Type 5–10% | Reduced imatinib response | SDH-deficient (young patients, gastric, indolent), NF1-associated, or BRAF mutant GISTs. Different biology — specialist referral essential. |
Surgery is the primary curative treatment for resectable GIST. No lymph node dissection is required. The most important surgical principle is avoiding tumour rupture.
The standard operation for gastric GIST — a wedge of stomach wall removed around the tumour with a 1–2 cm margin. No lymph node dissection required. Laparoscopic and robotic approaches preferred for most gastric GISTs, providing equivalent oncological outcomes with faster recovery.
Full Robotic GI Surgery Details →Small bowel GISTs require segmental resection of the involved bowel segment with en bloc mesentery — achieving clear margins. Primary anastomosis usually performed. Robotic or laparoscopic for smaller tumours; open for large, adherent, or multiple tumours.
Full Robotic GI Surgery Details →For large, locally advanced, or rectal GISTs — neoadjuvant imatinib (6–12 months) reduces tumour size and allows sphincter-preserving or minimally invasive resection. Response assessed with CT at 3 and 6 months using Choi criteria (look for density reduction — pseudo-response).
Full Robotic GI Surgery Details →Small gastric and rectal GISTs (typically <2 cm) can be removed endoscopically — by Endoscopic Submucosal Dissection (ESD) or Endoscopic Full-Thickness Resection (EFTR). Clear margins must be confirmed histologically. If margins are positive, surgical resection is required.
Full Robotic GI Surgery Details →Yes — GIST is a malignant tumour arising from the interstitial cells of Cajal in the GI tract wall. However, GISTs behave very differently from adenocarcinomas. They do not spread to lymph nodes, are highly sensitive to imatinib, and many patients — even with metastatic disease — live for many years. Prognosis is strongly linked to size, mitotic rate, and tumour location.
Imatinib is a targeted tyrosine kinase inhibitor that blocks the KIT and PDGFRA signalling pathways driving GIST growth. Before 2001, metastatic GIST had median survival under 2 years. With imatinib, many metastatic GIST patients now live 5–10+ years. For high-risk localised GIST, 3 years of adjuvant imatinib reduces recurrence by 50–60%.
Not always. Very small (<2 cm), asymptomatic, incidentally discovered low-risk GISTs may be managed with active surveillance. Endoscopic resection is appropriate for selected small gastric and rectal GISTs. For tumours >2 cm, or any symptomatic GIST, surgical resection is standard of care.
Rupture releases malignant GIST cells throughout the peritoneal cavity, causing peritoneal sarcomatosis — converting a potentially curable localised tumour into stage IV disease. The risk of peritoneal recurrence after rupture is very high. This is why GISTs must be resected carefully and intact at experienced centres.
PDGFRA D842V is a specific mutation found in 5–8% of GISTs — most often in gastric GISTs. This mutation is uniquely resistant to imatinib and sunitinib. However, Avapritinib (Ayvakit) achieves response rates exceeding 90% in PDGFRA D842V GIST. This is why molecular testing before starting treatment is mandatory for every GIST patient.
High-risk GIST: CT scan every 3–4 months for 3 years, then every 6 months for 2 years, then annually. Continue adjuvant imatinib for 3 years. Low-risk GIST: CT at 6 months, then annually for 5 years. Very low risk: annual CT or ultrasound for 5 years.
Bring your CT scan, endoscopy report, biopsy with IHC (CD117, DOG1, Ki-67), and molecular mutation report if available. Dr. Gore will review everything and discuss surgery, neoadjuvant imatinib if applicable, and the complete treatment plan.